Harmony Biosciences tumbles following Deutsche Bank, Truist downgrades
Source: SeekingAlpha
2026-02-23 13:57:55 ET
More on Harmony Biosciences
- Harmony Biosciences Makes The Grade
- Harmony Biosciences: Still Undervalued But Unappealing Risk/Reward (Downgrade)
- Harmony Biosciences Holdings, Inc. (HRMY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
- Harmony Biosciences Holdings, Inc. Q4 2025 Earnings Preview
- Harmony Bio granted FDA label expansion for Wakix in children with narcolepsy
Read the full article on Seeking Alpha
For further details see:
Harmony Biosciences tumbles following Deutsche Bank, Truist downgrades
Harmony Biosciences Holdings Inc.
NASDAQ: HRMY
HRMY Trading
2.79% G/L:
$28.88 Last:
153,089 Volume:
$28.51 Open:
HRMY Latest News
February 24, 2026 07:30:00 am
Harmony Biosciences Reports Strong 2025 Financial Results and Reiterates 2026 Net Revenue Guidance of Over $1 Billion
HRMY Stock Data
$2,184,629,859
44,003,618
0.12%
112
N/A
Biotechnology & Life Sciences
Healthcare
US
Plymouth Meeting
